Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Lancet Psychiatry. 2020 Jul 28;7(10):865–874. doi: 10.1016/S2215-0366(20)30290-X

Table 2.

Primary endpoint data. Means (95% Interval Estimates) stratified by group and time point at final analysis of placebo (n=23), 400mg CBD (n=24) and 800mg CBD (n=23) treatment arms

Placebo
 400mg
 800mg
Urinary THC-COOH: creatinine (ng/ml) Days abstinent from cannabis Urinary THC-COOH: creatinine (ng/ml) Days abstinent from cannabis Urinary THC-COOH: creatinine (ng/ml) Days abstinent from cannabis
Baseline 343.09
(188.41, 497.78)		 1.17
(0.48, 1.87)		 521.00
(316.55, 725.44)		 0.79
(0.34, 1.24)		 315.31
(150.00, 480.61)		 1.65
(0.68, 2.62)
Week 1 202.99
(68.59, 337.38)		 4.17
(3.29, 5.05)		 267.60
(71.61, 463.60)		 4.25
(3.40. 5.10)		 142.27
(70.65.213.90)		 4.04
(3.07. 5.01)
Week 2 187.53
(89.46.285.60)		 3.83
(2.77.4.88)		 227.17
(77.62.376.72)		 4.17
(3.26. 5.07)		 98.04
(53.89. 142.20)		 4.43
(3.55.5.32)
Week 3 185.53
(88.22. 282.84)		 4.36
(3.26. 5.46)		 272.31
(62.70. 481.92)		 4.67
(3.75. 5.58)		 125.73
(60 51.190.94)		 4.52
(3.63. 5.41)
Week 4 195.00
(92.08.297.92)		 4.14
(3.20.5.08)		 251.24
(95.38.407.11)		 4.38
(3.39. 5.36)		 144.07
(48 53.239.62)		 4.91
(4.05. 5.78)